Arbutus Biopharma (ABUS) News Today $3.90 -0.02 (-0.51%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 4:14 AM | americanbankingnews.comArbutus Biopharma (ABUS) Scheduled to Post Earnings on ThursdayJuly 23, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Sets New 1-Year High at $3.89Arbutus Biopharma (NASDAQ:ABUS) Hits New 12-Month High at $3.89July 20, 2024 | msn.comArbutus Biopharma to Reveal Q2 Financials and Corporate UpdatesJuly 18, 2024 | globenewswire.comArbutus to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateJuly 15, 2024 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 11.9% in JuneArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 6,010,000 shares, an increase of 11.9% from the June 15th total of 5,370,000 shares. Based on an average daily volume of 986,400 shares, the short-interest ratio is currently 6.1 days.July 12, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Hits New 1-Year High at $3.65Arbutus Biopharma (NASDAQ:ABUS) Sets New 1-Year High at $3.65July 8, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Up 4.2%Arbutus Biopharma (NASDAQ:ABUS) Trading 4.2% HigherJuly 5, 2024 | seekingalpha.comArbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard'July 5, 2024 | seekingalpha.comArbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy OpportunityJuly 2, 2024 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest UpdateArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totalling 5,370,000 shares, an increase of 6.8% from the May 31st total of 5,030,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is presently 4.2 days.June 26, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Shares Down 3.3% Arbutus Biopharma (NASDAQ:ABUS) Trading Down 3.3%June 26, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average of $2.74Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving Average of $2.74June 13, 2024 | marketbeat.comFourWorld Capital Management LLC Sells 251,056 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)FourWorld Capital Management LLC reduced its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,090,851 shares of the biopharmaceutical company's stock afteJune 6, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading Down 3%Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 3%June 6, 2024 | globenewswire.comTreatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsJune 6, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Thursday.June 5, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Wednesday.June 5, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.7%Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%June 5, 2024 | globenewswire.comArbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureJune 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Hits New 1-Year High at $3.44Arbutus Biopharma (NASDAQ:ABUS) Sets New 52-Week High at $3.44June 3, 2024 | globenewswire.comArbutus Distributors Ltd. News ReleaseJune 2, 2024 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Decline in Short InterestArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,340,000 shares, a drop of 8.1% from the April 30th total of 5,810,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 4.6 days.May 31, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Passes Above 200 Day Moving Average of $2.57Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above 200 Day Moving Average of $2.57May 29, 2024 | globenewswire.comArbutus to Participate in Jefferies Global Healthcare ConferenceMay 23, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Shares Down 4.7% Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%May 22, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.29Arbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $3.29May 22, 2024 | globenewswire.comArbutus to Present Imdusiran Data at EASL Congress 2024May 21, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%May 17, 2024 | morningstar.comArbutus Biopharma Corp ABUSMay 17, 2024 | bizjournals.comMike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus BiopharmaMay 17, 2024 | finance.yahoo.comArbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | finance.yahoo.comUpdate: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | businesswire.comWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueMay 10, 2024 | msn.comArbutus Biopharma to Engage Investors at Upcoming New York ConferencesMay 7, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMay 3, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)May 3, 2024 | finance.yahoo.comArbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 3, 2024 | finance.yahoo.comArbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.May 3, 2024 | msn.comArbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial ReleaseMay 2, 2024 | finance.yahoo.comArbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial ReviewMay 2, 2024 | investorplace.comABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | washingtonpost.comArbutus: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 2, 2024 | globenewswire.comArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024May 1, 2024 | markets.businessinsider.comArbutus Biopharma earnings: here's what to expectMay 1, 2024 | msn.comArbutus Biopharma Q1 2024 Earnings PreviewApril 30, 2024 | money.usnews.comArbutus Biopharma CorpApril 21, 2024 | msn.comArbutus Biopharma Sets Date for Q1 2024 Financial Results Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼0.570.61▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼42▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KALV News ALT News KMDA News RDHL News MORF News MOR News AGIO News BHC News PTCT News JANX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
